1. Adams AM, Serrano D, Buse DC, Reed ML, Marske V, Fanning KM, Lipton RB (2015) The impact of chronic migraine: the chronic migraine epidemiology and outcomes (CaMEO) study methods and baseline results. Cephalalgia 35:563–578
2. Ahmed F, Gaul C, Garcia-Monco JC, Sommer K, Martelletti P, Investigators RP (2019a) An open-label prospective study of the real-life use of on a botulinum toxin A for the treatment of chronic migraine: the REPOSE study. J Headache Pain 20:26
3. Ahmed F, Buture A, Tanvir T, Khalil M (2019b) Medication overuse does not affect response to OnabotulinumtoxinA treatment in patients with Chronic Migraine; update from real-life data from Hull Headache Clinic. In: Paper presented at the international headache congress. Dublin, Ireland, September 5–8, pp IHC-PO-397
4. Ahmed F, Buture A, Tanvir T, Khalil M (2019c) Analysis of patterns of response to OnabotulinumtoxinA in Chronic Migraine in predicting long-term outcome. In: Paper presented at the International Headache Congress. Dublin, Ireland, September 5–8, pp IHC-PO-398
5. Aicua-Rapun I, Martinez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, Porqueres E, Herrero S, Iglesias F, Guerrero AL (2016) Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin a during more than one year. J Headache Pain 17:112